Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer.

Authors: M Bottosso, F Mosele, S Michiels, P-H Cournède, S Dogan, C Labaki, F André

Journal: ESMO open

Publication Date: mars 2024

Abstract: Tumor heterogeneity represents a major challenge in breast cancer, being associated with disease progression and treatment resistance. Precision medicine has been extensively applied to dissect tumor heterogeneity and, through a deeper molecular understanding of the disease, to personalize therapeutic strategies. In the last years, technological advances have widely improved the understanding of breast cancer biology and several trials have been developed to translate these new insights into clinical practice, with the ultimate aim of improving patients' outcomes. In the era of molecular oncology, genomics analyses and other methodologies are shaping a new treatment algorithm in breast cancer care. In this manuscript, we review the main steps of precision medicine to predict drug sensitivity in breast cancer from a translational point of view. Genomic developments and their clinical implications are discussed, along with technological advancements that could broaden precision medicine applications. Current achievements are put into perspective to provide an overview of the state-of-art of breast cancer precision oncology as well as to identify future research directions.

DOI: 10.1016/j.esmoop.2024.102247

PMID:38401248

Share

 IHU PRISM founders

Where to find us

Prism  IHU

Bâtiment de médecine moléculaire

32 Rue Camille Desmoulins

94800 Villejuif

Tél. +33(0)1 42 11 00 00

info -at- prism.center

Liens

Press

Work with us

Call for project

Accessibility

Cookies Policy

Legal notice

Connect with us